Conversely, patients with both PD-L1-negative tumours and immune cells showed an improvement in OS rate (median OS, 10.2 months versus 8.3 months, respectively; HR, 0.51; 95% CI, 0.30–0.89) and PFS rate (median PFS, 5.4 versus 4.2 months; HR, 0.52; 95% CI, 0.31–0.88) receiving chemotherapy plus atezolizumab versus chemotherapy plus placebo. Here, CD274 is linked to neoplasm.